Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07002164

Timing of Coronary Angiography in NSTEMI Complicated by Acute HF

Study objectives:

To determine the optimal timing of coronary angiography (CAG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) complicated by acute decompensated heart failure (AHF). The primary objective of this trial is to test the hypothesis that immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.

Study hypothesis:

Immediate CAG ≤2 hours after establishment of NSTEMI diagnosis would result in a significant reduction in primary composite outcome of death from any cause, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF) at 12 months after randomization as compared with delayed CAG after stabilization.

Background:

Although current guidelines recommend early CAG within 2 hours for patients with NSTEMI complicated by AHF, many patients with NSTEMI complicated by AHF did not receive early CAG. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF. Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG <2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.

Study procedure:

Following the establishment of NSTEMI diagnosis, participants fulfilling the eligibility criteria will be randomized at a ratio of 1:1 to immediate CAG ≤2 hours after randomization or delayed CAG after stabilization on another day during hospitalization.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gyeongsang National University Changwon Hospital, Changwon, South Korea

Loading trial locations.

About this study

Acute decompensated heart failure (AHF) is frequently encountered in patients with non-ST-segment elevation myocardial infarction (NSTEMI), and it is known to be associated with worse clinical outcomes that those without heart failure (HF). Although current guidelines recommend immediate invasive strategy for patients with NSTEMI complicated by AHF, its evidence is lack. It is difficult to decide whether to perform early coronary angiography (CAG) according to the guidelines in these high-risk patients due to the risk of procedural complications. Furthermore, the most of randomized trials regarding the timing of CAG in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) have excluded these patients, therefore, there is lack of evidence for performing immediate CAG in such cases. In clinical practice, many patients with NSTEMI complicated by AHF did not receive early CAG. There are only two observational studies which investigated this issue. In the Korean nationwide registry data, a total of 1,027 patients with NSTEMI complicated by AHF were analyzed, and 14.5% among study population underwent early CAG within 2 hours according to the guidelines. All-cause mortality at 12 months was not significantly different irrespective of CAG timing. In other single-center study, early CAG <24 hours was associated with a lower risk of adverse cardiac outcomes compared with delayed CAG ≥24 hours after admission.

Several studies have demonstrated improved clinical outcomes in high-risk patients with NSTE-ACS undergoing early CAG, whereas others have found no significant differences in clinical outcomes. Randomized clinical trials, such as SISCA, ISAR-COOL, RIDDLE-NSTEMI and EARLY, have demonstrated the advantages of early CAG compared to delayed invasive approach (i.e. CAG after stabilization) in high-risk patients with NSTE-ACS. The other trials regarding this issue have failed to show the superiority of early CAG over delayed invasive approach. However, no randomized clinical trials have evaluated the optimal timing of CAG in patients with NSTEMI complicated by AHF.

Therefore, the investigators aimed to perform a prospective, investigator-initiated, open-label, muilticenter trial to compare the efficacy and safety between immediate CAG (CAG <2 hours after establishment of NSTEMI diagnosis) and delayed CAG after stabilization (i.e. improved dyspnea and disappearance of pulmonary congestion) in participants with NSTEMI complicated by AHF.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥19 years
  • Non-ST-segment elevation myocardial infarction
  • New-onset or worsening of dyspnea (New York Heart Association class ≥2)
  • Pulmonary congestion
  • Patient's or guardian's consent after understanding the study

Exclusion criteria

  • Cardiogenic shock at initial presentation
  • ST-segment elevation myocardial infarction
  • ST-segment elevation ≥0.1 mV in at least 2 contiguous leads, or
  • New onset left bundle branch block
  • Posterior wall myocardial infarction
  • Refractory angina
  • Life threatening ventricular arrhythmias
  • Life expectancy <1 year
  • Apparently non-ischemic cause of HF
  • Pregnancy and lactation
  • History of coronary artery bypass grafting (CABG), or planned CABG
  • Patient's refusal to participate in study

Treatment and study plan

Immediate coronary angiography

Procedure

Immediate coronary angiography ≤2 hours after randomization

Delayed coronary angiography

Procedure

Delayed coronary angiography after stabilization

Primary outcomes

  1. A cumulative incidence rate of all-cause death, non-fatal myocardial infarction (MI), or hospitalization for heart failure (HF)

    Time frame: 1 year

Secondary outcomes

  1. A cumulative incidence rate of all-cause death, non-fatal MI, or hospitalization for HF

    Time frame: 1, 6, 24, 36 months

  2. All-cause death

    Time frame: 1, 6, 12, 24, 36 months

  3. Non-fatal MI

    Time frame: 1, 6, 12, 24, 36 months

  4. Hospitalization for HF

    Time frame: 1, 6, 12, 24, 36 months

  5. Cardiovascular death

    Time frame: 1, 6, 12, 24, 36 months

  6. Recurrent ischemia

    Time frame: 1, 6, 12, 24, 36 months

    Recurrent ischemia is defined as repeated episodes of ischemic symptoms needing emergent coronary angiography with any of the following signs:

    • Electrocardiographic changes indicating myocardial ischemia
    • Ventricular arrhythmias
    • New-onset pulmonary edema
    • Cardiogenic shock
  7. All unplanned revascularization

    Time frame: 1, 6, 12, 24, 36 months

  8. Definite or probable stent thrombosis

    Time frame: 1, 6, 12, 24, 36 months

  9. Stroke

    Time frame: 1, 6, 12, 24, 36 months

  10. Major bleeding by Bleeding Academic Research Consortium

    Time frame: 1, 6, 12, 24, 36 months

  11. Acute kidney injury (AKI) and AKI requiring renal replacement therapy

    Time frame: Up to 7 days

  12. In-hospital death rate from any cause

    Time frame: Up to 30 days

  13. In-hospital death rate from cardiovascular cause

    Time frame: Up to 30 days

Study contacts

Contact information is provided by the study sponsor or research team.

Min Chul Kim, Professor

CONTACT

[email protected]

82-62-220-6578 ext. 82-62-220-6578

Youngkeun Ahn, Professor

CONTACT

[email protected]

82-62-220-4764 ext. 82-62-220-4764

Sponsors and collaborators

Lead sponsor

Chonnam National University Hospital

Other

Registry information

Official study title

Trial of IMmediate Invasive Versus Delayed Coronary ANGiography in Non-ST-Segment Elevation Myocardial Infarction Complicated by Acute Decompensated Heart Failure: The TIMING-AHF Trial

Acronym: TIMING-AHF

Important dates

Study start
2025
Primary completion
2030
Study completion
2032
First posted
Jun 3, 2025
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.